Agios Pharmaceuticals Inc
NASDAQ:AGIO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.97
49.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Agios Pharmaceuticals Inc
Wall Street
Price Targets
AGIO Price Targets Summary
Agios Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
AGIO
is 57.12 USD
with a low forecast of 52.52 USD and a high forecast of 63 USD.
AGIO Last Price Targets
Agios Pharmaceuticals Inc
The latest public price target was made on Sep 27, 2024 by
Andrew Berens
from
Leerink Partners
,
who expects
AGIO
stock to
rise by 31%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Andrew Berens
Leerink Partners
|
56
USD
Upside 31% |
2 weeks ago
Sep 27, 2024
|
Leerink Partners Downgrades Agios Pharma (AGIO) to Market Perform
StreetInsider
|
Chris Raymond
Raymond James
|
56
USD
Upside 31% |
1 month ago
Sep 10, 2024
|
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
StreetInsider
|
|
Chris Raymond
Raymond James
|
55
USD
Upside 29% |
3 months ago
Jun 17, 2024
|
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
StreetInsider
|
Gregory Renza
RBC Capital
|
53
USD
Upside 24% |
4 months ago
Jun 3, 2024
|
Agios Pharmaceuticals price target raised to $53 from $44 at RBC Capital
TheFly
|
|
Chris Raymond
Raymond James
|
45
USD
Upside 6% |
4 months ago
May 28, 2024
|
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
StreetInsider
|
Unknown Analyst
Piper Sandler
|
41
USD
Downside 4% |
1 year ago
Feb 3, 2023
|
Piper Sandler Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces Price Target of $41
Benzinga
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is AGIO's stock price target?
Price Target
57.12
USD
According to Wall Street analysts, the average 1-year price target for
AGIO
is 57.12 USD
with a low forecast of 52.52 USD and a high forecast of 63 USD.
What is Agios Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
91%
For the last 8 years the
compound annual growth rate for
Agios Pharmaceuticals Inc's revenue is
-9%.
The projected
CAGR
for the next 3 years is
91%.
You don't have any saved screeners yet
